# Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

> **NCT02960893** · PHASE2,PHASE3 · COMPLETED · sponsor: **Biohaven Pharmaceuticals, Inc.** · enrollment: 141 (actual)

## Conditions studied

- Spinocerebellar Ataxias
- Spinocerebellar Ataxia Genotype Type 1
- Spinocerebellar Ataxia Genotype Type 2
- Spinocerebellar Ataxia Genotype Type 3
- Spinocerebellar Ataxia Genotype Type 6
- Spinocerebellar Ataxia Genotype Type 7
- Spinocerebellar Ataxia Genotype Type 8
- Spinocerebellar Ataxia Genotype Type 10

## Interventions

- **DRUG:** Troriluzole
- **DRUG:** Placebo
- **DRUG:** Troriluzole

## Key facts

- **NCT ID:** NCT02960893
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-15
- **Primary completion:** 2017-08-18
- **Final completion:** 2024-09-20
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960893, "Trial in Adult Participants With Spinocerebellar Ataxia (SCA)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02960893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*